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A small toolkit of morphogens is used repeatedly to
direct development, raising the question of how
context dictates interpretation of the same cue.
One example is the transforming growth factor b
(TGF-b) pathway that in human embryonic stem cells
fulfills two opposite functions: pluripotency mainte-
nance and mesendoderm (ME) specification. Using
proteomics coupled to analysis of genome occu-
pancy, we uncover a regulatory complex composed
of transcriptional effectors of the Hippo pathway
(TAZ/YAP/TEAD), the TGF-b pathway (SMAD2/3),
and the pluripotency regulator OCT4 (TSO). TSO
collaborates with NuRD repressor complexes to
buffer pluripotency gene expression while suppress-
ing ME genes. Importantly, the SMAD DNA binding
partner FOXH1, a major specifier of ME, is found
near TSO elements, and upon fate specification
we show that TSO is disrupted with subsequent
SMAD-FOXH1 induction of ME. These studies define
switch-enhancer elements and provide a framework
to understand how cellular context dictates interpre-
tation of the samemorphogen signal in development.
INTRODUCTION
Human embryonic stem cells (hESCs) are derived from the inner
cell mass of the blastocyst and are defined by their ability to self-
renew andmaintain pluripotency in culture. hESCs can be differ-
entiated into all functional cell types and are expected to be a
powerful therapeutic tool for multiple human diseases. Further-
more, hESCs serve as a model system for early human embry-
onic development (Hanna et al., 2010). Thus, understanding
the molecular mechanisms underlying self-renewal and cell
fate decision in hESCs is a critical goal. Since the advent ofCell RehESCs in 1998 (Thomson et al., 1998), countless studies have
elaborated the transcriptional basis of these cells using a wide
variety of techniques. The molecular fundamentals of pluripo-
tency are defined by the core transcriptional circuitry consisting
of OCT4, NANOG, and SOX2 (Young, 2011). These factors have
two main functions: (1) they regulate and stabilize each other’s
expression by forming an autoregulatory loop, and (2) they regu-
late pluripotency by activating genes important for maintaining
the hESC state while suppressing genes important for lineage
specification. This is achieved by cooperation of the core factors
with transcription factors that act downstream of extracellular
signaling pathways such as leukemia inhibitory factor and
bone morphogenetic protein (BMP) for murine embryonic stem
cells and fibroblast growth factor (FGF) and ACTIVIN/NODAL/
TGF-b for hESCs, respectively (Beyer et al., 2013).
ACTIVIN/NODAL/TGF-b are morphogens of the transforming
growth factor b (TGF-b) signaling pathway. They bind as dimers
to serine/threonine kinase receptors termed type II receptors
(ACTR IIA/B, TGFBRII). This leads to the recruitment of the
type I receptor (ALK4/5/7), resulting in receptor activation and
subsequent phosphorylation of the downstream effectors
SMAD2/3 (Weiss and Attisano, 2013). SMAD2/3 are transcrip-
tional regulators that form a heteromeric complex with SMAD4
and other cell-type-specific coactivators and/or corepressors
to control target gene expression (Beyer et al., 2013). Here, for
simplicity, we will refer to the ACTIVIN/NODAL/TGF-b pathway
as SMAD2/3 signaling. Several reports have shown that
SMAD2/3 signaling is essential for themaintenance of the plurip-
otent state (James et al., 2005) as well as for the induction of the
primitive streak at the onset of gastrulation and the subsequent
specification of the anterior primitive streak (APS) andmesendo-
derm (ME) (Tam and Loebel, 2007). Recent reports show that
expression of NANOG in hESCs is dependent on SMAD2/3
signaling (Greber et al., 2008), thereby stabilizing pluripo-
tency. Furthermore, chromatin immunoprecipitation sequencing
(ChIP-seq) studies revealed that SMADs cooperate with OCT4
and NANOG to regulate the expression of a subset of their target
genes in hESCs (Brown et al., 2011; Mullen et al., 2011). On theports 5, 1611–1624, December 26, 2013 ª2013 The Authors 1611
other hand, during gastrulation, SMAD2/3 induces formation of
ME via induction of genes such as EOMES, GSC, T, and
FOXA2 (Tam and Loebel, 2007). This is achieved via cooperative
action of SMAD2/3-SMAD4 complexes with the forkhead tran-
scription factor FOXH1 (Labbe´ et al., 1998). Indeed, Foxh1 null
mice show defects in the specification of the anterior primitive
streak, axial patterning, and endoderm development (Hoodless
et al., 2001; Yamamoto et al., 2001). Interestingly, Foxh1 is
already expressed in the mouse epiblast prior to specification
of ME (Labbe´ et al., 1998), and in hESCs FOXH1 is expressed
and bound to a subset of its ME targets even in the undifferenti-
ated state (Kim et al., 2011). This raises several questions, such
as how do cells interpret SMAD2/3 signaling in pluripotent
versus differentiating conditions, and what regulates the activity
of cell-fate specification pathways if master regulators such as
FOXH1 are already expressed in the pluripotent state?
Here, we used an integrated proteomics and genomics
approach to address how SMAD2/3 signaling is interpreted in
pluripotent cells versus ME specification. We identify a regula-
tory complex composed of the downstream components of
the Hippo pathway, TAZ/YAP and TEADs, as well as SMAD2/3
and OCT4 (termed TSO). TSO acts to suppress the expression
of differentiation markers and modulates the levels of core plu-
ripotency genes, therebymaintaining pluripotency. Furthermore,
FOXH1 is found near TSO elements at key ME target genes, and
upon ME specification, we show that the repressive function of
TSO is lost and SMAD2/3 signaling cooperates with FOXH1 to
drive ME specification. We thus define a class of enhancer ele-
ments that we term switch elements, which act to direct discrete
SMAD2/3 signaling outcomes in the context of pluripotency and
ME induction.
RESULTS
Identification of SMAD Cofactors in hESCs
In hESCs, expression ofNANOG is crucial for pluripotency and is
dependent on the core embryonic transcription factors OCT4,
SOX2, and NANOG (Boyer et al., 2005) as well as SMAD2/3,
the downstream transcriptional effectors of the ACTIVIN/
NODAL/TGF-b pathway. OCT4 and SOX2 act in part by
converging on composite regulatory elements such as the
SOX/OCT motif found in the promoter region of the NANOG
gene (Greber et al., 2008). SMAD2/3 signaling can also converge
on these elements via physical interactions with OCT4 (Mullen
et al., 2011) and SMAD-binding elements (SBE) found close to
the SOX/OCT site (Greber et al., 2008). To identify protein com-
plexes that propagate SMAD2/3 signaling during pluripotency
maintenance, we employed the SOX/OCT element embedded
in a 400 bp fragment of the NANOG promoter (NANOG400) in
an affinity-purification proteomics strategy (Figure 1A). Analysis
of bound complexes by mass spectrometry and immunoblotting
revealed that OCT4 and NANOG bound to the NANOG400 frag-
ment as well as SMAD2 and its partner SMAD4 (Figure 1B).While
inhibition of SMAD2/3 signaling using the selective ACTIVIN/
NODAL/TGF-b receptor antagonist SB431542 (Ogunjimi et al.,
2012) abolished SMAD2 binding, NANOG and OCT4 binding
was unaffected (Figures 1B and 1C). Of note, SMAD4 binding
was also maintained in the presence of inhibitor (Figure 1B),1612 Cell Reports 5, 1611–1624, December 26, 2013 ª2013 The Autconsistent with previously published work showing that BMP-
regulated SMADs can recruit SMAD4 to this site upon inhibi-
tion of SMAD2/3 signaling (Xu et al., 2008). Interestingly,
NANOG400-bound proteins included TAZ and YAP, the key tran-
scriptional effectors of the Hippo signaling pathway, as well as
their DNA binding partners, the TEA domain transcription factors
TEAD1, 3, and 4 (Figures 1B and 1D; data not shown). The Hippo
pathway controls tissue growth, organ size, tumorigenesis, and
cell fate. Activation of the core kinases MST1/2 and LATS1/2
by a variety of mechanisms such as cell-cell contact leads to
phosphorylation of TAZ/YAP and subsequent cytoplasmic
sequestration and inactivation (Varelas and Wrana, 2012). TAZ
and/or YAP are crucial for pluripotency in hESCs and mouse
embryonic stem cells (mESCs) (Lian et al., 2010; Varelas et al.,
2008). Interestingly, TAZ and YAP regulate SMAD2/3 activity
by controlling the subcellular localization of SMAD complexes
(Varelas et al., 2008, 2010). Furthermore, Tead2 has been shown
to be essential in maintenance of pluripotency in mESCs (Tamm
et al., 2011). However, the function of this transcription factor
family in hESCs has not been addressed.
Analysis of NANOG400 revealed a TEAD consensus motif
within the SOX/OCT binding site. To explore whether this
element is critical for TEAD association, we tested a minimal
80 bp NANOG promoter fragment (NANOG80) composed of
wild-type or mutant variants of the SBE, OCT4, and TEAD bind-
ing sites (Figure S1) (Xu et al., 2008). Combined mutation of the
SBE, OCT4, and TEAD elements (NANOG80mut) reduced or
abolished binding of OCT4, SMADs, TEADs, and the TEAD part-
ner YAP, while mutation of the overlapping TEAD/SOX/OCT site
(NANOG80Tdmut) interfered with TEAD, YAP, and OCT4 binding
only (Figures 1D and S1). To verify the association of these
transcription factors with the endogenous NANOG promoter,
we performed ChIP. SMAD2 associated with the region in an
ACTIVIN signaling-dependent manner, whereas binding of
OCT4 was independent of signaling, as previously reported (Fig-
ure 1E). Furthermore, TEAD4 remained associated with the pro-
moter element independent of SMAD2/3 signaling, confirming
our analysis by affinity purification (Figure 1E). Thus, both Hippo
and SMAD2/3 signaling components engage the NANOG
promoter along with pluripotency transcription factors. These
results hint towards a regulation of the NANOG promoter by
the Hippo pathway, in concert with SMAD2/3 signaling and plu-
ripotency transcription factors.
OCT4, SMADs, and the Transcriptional Components of
the Hippo Pathway Form a Complex
The close proximity of OCT4, SMAD, and TEAD binding ele-
ments on the NANOG promoter prompted us to test their phys-
ical interaction. For this, we performed binary interaction studies
in human embryonic kidney 293T (HEK293T) cells using either
LUMIER (illustrated in Figure 2A) or conventional coimmunopre-
cipitation assays. We observed that OCT4 interacted with TAZ,
YAP (Figure 2A), and TEAD1-4 (Figure S2A). OCT4 also bound
SMAD2/3 (Figure S2B), confirming previous studies (Mullen
et al., 2011). Furthermore, SMAD2/3 and the co-SMAD SMAD4
bound TEAD1-4 (Figures S2C and S2D) as previously published
(Fujii et al., 2012). To determine if SMADs, TAZ/YAP and TEADs
engage in a common complex, we next performed two-stephors
Figure 1. Identification of Transcriptional
Cofactors Regulating NANOG Expression
(A) Biotinylated oligonucleotides corresponding
to the NANOG promoter were used as bait to
capture DNA binding proteins from hESC lysates.
Precipitated proteins were analyzed by western
blot or mass spectrometry. To remove general
DNA binding proteins, nonbiotinylated nonspecific
competitor DNA was used.
(B) Summary of identified proteins in the presence
and absence of ACTIVIN signaling. hESCs treated
for 4 hr with solvent control (DMSO) or 10 mM
SB431542 (SB) were lysed and subjected to DNA
pull-down with NANOG400. Precipitates were
analyzed by mass spectrometry. ‘‘+’’ indicates
binding, whereas ‘‘’’ denotes loss of binding.
(C) Lysates from hESCs treated as described were
used for DNA pull-down and analyzed by immu-
noblot. Total cell lysates served as input controls.
(D) DNA pull-down was performed with NANOG80
mutant DNA fragments for SMAD/OCT4/TEAD
sites (mut) and the overlapping OCT4/TEAD site
(Tdmut). See Figure S1 for sequence details.
(E) ChIP-qPCR with primers corresponding to the
NANOG promoter was performed. hESCs were
treated as above and ChIP was performed with
antibodies against OCT4, SMAD2, and TEAD4.
Fold enrichment was calculated over mock
precipitation using species-matched normal IgG.
Bars represent average ± SEM (nR 3).coimmunoprecipitation (illustrated in Figure 2B). This revealed
that TAZ interacted with TEAD4 independent of SMAD2/3
signaling, as expected, whereas SMAD3 activation by a
constitutively active type I receptor enhanced formation of a
SMAD-TAZ-TEAD complex (Figure 2B). Furthermore, immuno-
precipitation of either OCT4 or SMAD2 from hESC lysates
showed endogenous interactions of both proteins with TEAD4
(Figure 2C). To assess whether all four factors form a complex
in hESC, we fractionated nuclear extracts. Upon gel filtration,
OCT4, SMAD2, TEAD4, and TAZ/YAP showed broad elution
profiles consistent with engagement in diverse protein com-
plexes and cofractionated with an estimated molecular weightCell Reports 5, 1611–1624, Deof more than 200 kDa (Figures S2E and
S2F). We subsequently fractionated this
complex by anion exchange chromatog-
raphy and observed that the bound
factors copurified during salt gradient
elution (Figure 2D). Collectively, these re-
sults indicate that Hippo and SMAD2/3
pathway components converge with the
pluripotency factor OCT4 to form a com-
plex that we refer to as the TSO (TEAD-
SMAD-OCT4) complex (Figure 2E).
Genome-wide Occupancy of the
TSO Complex in hESCs
Our results indicate that TSO binds to
regulatory elements at the NANOG locus,
and previous results showed a crucialrole of TAZ/YAP/TEADs in regulating pluripotency (Lian et al.,
2010; Tamm et al., 2011; Varelas et al., 2008). We therefore
speculated that TSO is not limited to the NANOG promoter
and controls a larger number of pluripotency elements in hESCs.
To examine this, we performed genome-wide ChIP-seq analysis
for TEADs and SMADs in hESCs using TEAD4 and SMAD2
antibodies. We tested these antibodies extensively to confirm
their suitability for ChIP-seq (Figures S3A and S5A; details in
Supplemental Experimental Procedures). ChIP-seq was subse-
quently performed in hESCs in the presence or absence of
the SMAD2/3 signaling inhibitor SB431542 using input DNA
and species-matched immunoglobulin G (IgG) as backgroundcember 26, 2013 ª2013 The Authors 1613
Figure 2. TAZ/YAP/TEAD, SMADs, and OCT4 Form a Macromolecular Complex
(A) TAZ and YAP interact with OCT4. hRLuciferase-OCT4 and 33FLAG-TAZ (middle) or 33FLAG-YAP (right) were overexpressed in HEK293T cells in the
presence or absence of the constitutively active TGF-b receptor TGFBR1T204D. Interaction was tested by LUMIER (schematic left). Representative experiments
are shown (n = 3).
(B) SMAD3, TAZ, and TEAD4 form a TGF-b-dependent complex. 33FLAG-TEAD4, hRLuciferase-TAZ, and 33HA-SMAD3were overexpressed in HEK293T cells
in the presence or absence of TGFBR1T204D. Double coimmunoprecipitation was performed as depicted and the interaction determined by LUMIER.
Representative experiments are shown (n = 3)
(C) OCT4 and SMAD2 interact with TEAD4 endogenously. OCT4 and SMAD2 protein complexes were precipitated from hESC lysates and the presence of TEAD4
was detected by immunoblotting. Mock precipitation using species-matched normal IgG served as negative control (n = 3).
(D) SMAD2, TAZ, TEAD4, and OCT4 form a complex in vivo. Nuclear extracts from hESCs were fractionated by size exclusion chromatography followed by ion
exchange chromatography. Fractions 3 to 12 were resolved by SDS-PAGE and immunoblots performed as indicated.
(E) Schematic representation of the TSO complex.controls. We first verified binding of TEAD4 and SMAD2 to the
CTGF promoter and the LEFTY1 enhancer, respectively (Fig-
ure S3B), and confirmed dramatic reduction in SMAD2 genome
occupancy upon SB431542 treatment, as illustrated for the
LEFTY1 locus (Figure S3B, lower panel). Inclusion of this control1614 Cell Reports 5, 1611–1624, December 26, 2013 ª2013 The Autincreased our ChIP-seq sensitivity, as reflected by more SMAD
binding sites identified here when compared to others (Brown
et al., 2011; Mullen et al., 2011). Indeed, de novo motif discovery
revealed enrichment for GC-rich sequences (motif 1; Fig-
ure S3C), similar to SMAD2-SMAD4 binding sites previouslyhors
characterized close to developmental genes (Labbe´ et al., 1998).
We also identified a second motif (motif 2; Figure S3C) that is
similar to the SMAD4 binding site (Massague´ et al., 2005). Of
note, while SMAD3 directly binds DNA, the closely related
SMAD2 does not and relies on the DNA binding domain of its
SMAD4 partner to establish stable complexes on target ele-
ments (Labbe´ et al., 1998). This likely accounts for this second
SMAD4-like motif. Similar unbiased motif discovery using the
TEAD4 ChIP-seq data identified a TCCATTCC motif, which cor-
responds to theRCATTCCWTEAD1site in JASPAR (Figure S3D).
Subsequently, we determined the occurrence of TEAD con-
sensus sites in genomic loci identified by TEAD4 ChIP-seq and
found that the TEAD bindingmotif was enriched when compared
with a complement control sequence (Figure S3E).
To identify genomic regions bound by TEAD4, SMAD2, and
OCT4 in hESCs, we integrated our data with a published hESC
OCT4 ChIP-seq data set (Kunarso et al., 2010). We first exam-
ined NANOG as well as POU5F1 (OCT4), both well-character-
izedOCT4 target genes, and observed conserved regions bound
by all three factors (Figure 3A). Interestingly, our ChIP-seq data
revealed a more distal conserved TSO site in the NANOG locus
that highlights a potential alternative site of regulation (Figure 3A).
ChIP quantitative PCR (qPCR) analysis confirmed ACTIVIN-
dependent SMAD2 binding as well as signaling-independent
TEAD4 and OCT4 binding to their respective sites (Figure 3B).
To demonstrate that TEAD4, SMAD2, and OCT4 simultaneously
bind to the same site, we performed sequential ChIP experi-
ments. Chromosomal DNA was precipitated using an OCT4
antibody followed by a second immunoprecipitation using anti-
bodies to SMAD2 or TEAD4. We observed binding of SMAD2
as well as TEAD4 to the NANOG and LEFTY1 TSO element after
prepurification with the OCT4 antibody (Figure 3C). These find-
ings confirm that the TSO complex is bound to pluripotency tar-
gets in hESCs.
We next expanded our analysis of TSO complexes in hESCs,
by extending our search to all sites where TEAD4, SMAD2, and
OCT4 are cobound within a 200 bp window. This resulted in
1,329 peaks (p < 106, c2 = 16,225, with c2 indicating goodness
of fit; Figure 3D; Table S1), that fell within 50 kb upstream and
10 kb downstream of 933 genes (Table S1). For comparison, a
random distribution over the genome yielded only 94 cobound
regions. In addition to NANOG and POU5F1, these triple-bound
peaks were found adjacent to other important pluripotency
genes, such as LIN28A, NR5A2, DPPA3, GDF3, SATB1, TBX3,
UTF1, and FOXP1. We selected a subset of genes (LIN28A,
NR5A2, and GDF3/DPPA3) to verify these results by ChIP-
qPCR (Figures S4A and S4B), which showed that of the three
factors, only SMAD2 was dependent on ACTIVIN signaling.
These results support the notion that SMAD2 and TEAD4 broadly
converge with OCT4 on numerous pluripotency-associated
genes in hESCs.
Our analysis of pluripotency TSO targets led us to hypothesize
that transcriptional effectors of the Hippo pathway direct
SMAD2/3 action toward the maintenance of pluripotency. To
assess this across all TSO peaks, we performed a GREAT anal-
ysis (McLean et al., 2010). This revealed a high enrichment of
terms associated with stem cell regulation (Figure 3E; Table
S2). Surprisingly, however, the greatest enrichment was forCell Reterms associated with ME differentiation and embryo develop-
ment, in particular primitive streak, endoderm formation, and
gastrulation. These genes included FOXA2, EOMES, GSC, and
T (BRACHYURY) (Figures 4A and 6C), all of which were verified
by ChIP-qPCR to be bound by TSO (Figure S4C; data not shown)
with SMAD2 dependent on ACTIVIN signaling (Figure S4C).
These results demonstrate that TSO binding is not restricted to
pluripotency genes, and might also function to regulate cell
fate specification genes during ME induction.
TSO Suppresses ME Formation
To explore the function of TSO-bound elements in hESCs, we
abrogated the expression of TEADs, TAZ, and YAP using small
interfering RNAs (siRNAs). Single knockdown of TEAD family
members yielded no obvious defects in pluripotency, survival,
or proliferation (data not shown), most likely due to redun-
dancy, since all four TEAD isoforms are expressed in hESCs.
In our previous studies on hESCs, we observed that TAZ
prevented neurectoderm specification and maintained pluripo-
tency by regulating TGF-b-dependent nuclear accumulation of
SMAD2/3 (Varelas et al., 2008). Recent reports, however, indi-
cate that the culture conditions employed in those experiments
(X-VIVO) were suboptimal for hESC culture and lead to ectopic
differentiation (Akopian et al., 2010). This prompted us to alter
culture conditions to murine embryonic fibroblast (MEF)-condi-
tioned medium with Matrigel for all of our experiments, which
is considered more robust (Xu et al., 2001). Interestingly, knock-
down of TAZ only moderately affected SMAD2/3 localization
(Figure S5A), suggesting that under these culture conditions,
YAP might provide redundant functions, as noted before (Vare-
las et al., 2010). Indeed, double knockdown of both TAZ and
YAP reduced SMAD2/3 nuclear accumulation (Figure S5A) and
strongly suppressed expression of CTGF, a well-known TAZ/
YAP-TEAD target gene (Zhao et al., 2008) (Figure S5B). These-
results indicate that in MEF-conditioned media and Matrigel,
both TAZ and YAP contribute to pluripotency maintenance.
Therefore, for subsequent analyses, we knocked down both
TAZ and YAP.
To overcome TEAD redundancy, we designed a single siRNA
that simultaneously targets TEADs 1, 3, and 4 and used it
together with a TEAD2 siRNA. This yielded an overall reduction
of TEADmRNA levels of 80%, with concomitant downregulation
of CTGF (Figure S5C). To rule out the possibility of off-target
effects, we also designed a siRNA that simultaneously targets
both TAZ and YAP, which yielded similar effects (data not
shown).We next employedmicroarray expression profiling using
BeadArray technology of siTEAD1-4 and siTAZ/YAP-treated
hESCs 48 hr after transfection. This revealed 1,417 and 1,553
probes, respectively, with greater than 2-fold change in expres-
sion (Figure S6A), with 977 probes (69% and 63%, respectively)
commonly affected (Figure S6B; Table S3). This large overlap in-
dicates that TEADs are the major DNA-binding effector partners
of TAZ/YAP in hESCs. Subsequently, we focused on the TSO-
marked genes present in our microarray data (Figure 4B, 738
probes) and found that 60 (TAZ/YAP) and 54 (TEAD1–4) genes
were downregulated and 50 (TAZ/YAP) and 43 (TEAD1–4) genes
were upregulated. To our surprise, pluripotency-associated
genes such as POU5F1, NANOG, LIN28A, GDF3, NR5A2, andports 5, 1611–1624, December 26, 2013 ª2013 The Authors 1615
Figure 3. Genome-wide Identification of TSO Targets in hESCs
(A) TEAD4, SMAD2, and OCT4 (TSO) binding at the POU5F1/OCT4 and NANOG loci overlap. TSO peaks are represented by magenta, green, and brown bars.
Conservation among species is indicated as black bars. Red boxes indicate colocalization of the peaks identified. Distances are relative to the transcriptional start
site (TSS).
(B) Verification of TSO binding regions by ChIP-qPCR. ChIP-qPCR was performed using the indicated antibodies and primer sets. hESCs were treated as above
and fold enrichment was calculated over mock precipitation using species matched normal IgG. Bars represent mean ± SEM (nR 3).
(C) OCT4/SMAD2 and OCT4/TEAD4 bind to TSO sites simultaneously. ChIP was performed using OCT4 or control antibody and the precipitates were eluted and
used either for qPCRwith the indicated primer sets (first immunoprecipitation, white and black bars) or in a sequential ChIP with antibodies against SMAD2 (green
bars) or TEAD4 (purple bars). Fold enrichment was calculated over mock precipitation using species-matched normal IgG. Bars represent mean ± SEM (nR 3).
(D) Genome-wide identification of TSO-bound regions. VENN diagrams show the ratio of overlapping peaks from the three data sets. SMAD2/TEAD4 overlaps are
represented in yellow, TEAD4/OCT4 overlaps in light blue, and TEAD4/OCT4/SMAD2 overlaps (TSO peaks) in white.
(E) Genes associated with early embryonic functions are overrepresented among genes adjacent to TSO peaks. Functional annotation of TSO peaks was
performed using GREAT. Scale bars depict fold overrepresentation and p values are raw binominal values.
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Figure 4. TSO Peaks Regulate Pluripotency and Mesendoderm Induction
(A) TSO binds to the FOXA2, EOMES, T/BRACHYURY, and GDF3/DPPA3 loci. Individual peaks are represented by green (SMAD2), magenta (TEAD4), or brown
(OCT4) bars. Conservation among species is indicated as black bars. Red boxes indicate colocalization of the peaks identified. Distances are relative to the TSS
or transcriptional end site (TES; for FOXA2 and GDF3).
(B) Expression profiling of TSO genes after TEAD1–4 or TAZ/YAP knockdown. Expression levels of TSO genes in hESCs were determined 48 hr after siRNA-
mediated knockdown of TEAD1–4 or TAZ/YAP and plotted as a heatmap. Each row was normalized to have a mean of zero and a variance of one. Red indicates
upregulation and green downregulation. Fold-change values (log2) over control-treated cells are depicted for a selection of TSO genes.
(C) FOXA2/T and OCT4 are coexpressed in hESCs depleted of TEAD1–4 or TAZ/YAP. hESCs were treated with siRNA as indicated for 72 hr and fixed and stained
with antibodies to FOXA2 (red) and OCT4 (green) (upper panel) or T (red) and OCT4 (green) (lower panel).
(D) SMAD2andOCT4bind independently of TAZ/YAPor TEADs toTSO regions. ChIP-qPCRwasperformedusing the indicated antibodies andprimer sets. hESCs
were treated as indicated and the amount of precipitated DNA is represented as signal relative to the amount of input DNA. Bars represent mean ± SEM (nR 3).
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DPPA3were not suppressed but rather elevated (Figure 4B, right
panel). This was verified by qPCR (Figure S6C, left panel), which
confirmed strong increases inGDF3 andDPPA3 expression (Fig-
ure S6C, middle panel). In addition, we found that TSO genes
associated with formation of the primitive streak and in particular
ME, such as FOXA2, EOMES, GSC, KDR and T, were dramati-
cally induced (Figure 4B), which was also confirmed by qPCR
(Figure S6D).
Our data suggest that TSO acts as a repressive complex on
genes associated with both pluripotency and ME cell fate. We
therefore expanded our analysis to pluripotency and ME genes
not associated with TSO. This showed that loss of either TAZ/
YAP or TEADs induced non-TSO-marked ME genes such as
FGF8, WNT3A, NODAL, and ISL1 after 72 hr (Figure S6D). In
striking contrast to the elevated TSO-marked pluripotency genes
POU5F1 and NANOG, expression of non-TSO-marked pluripo-
tency genes, such as FGF2 and SOX2, declined (Figure S6C,
right panel). We confirmed these observations at the protein level
and observed slightly increased NANOG levels and unchanged
OCT4 levels with dramatic induction of T and FOXA2 levels after
TEADs or TAZ/YAP knockdown (Figure S6E). Immunofluores-
cence similarly revealed the appearance of abundant OCT4
and FOXA2 or T double-positive cells (Figure 4C). Furthermore,
double staining of hESCs with antibodies against TAZ/YAP as
well as EOMES 96 hr after TAZ/YAP knockdown showed that
induction of EOMES was dependent on loss of TAZ/YAP at the
cellular level (Figure S6F). These results are consistent with pre-
vious studies showing that during the early stages of ME speci-
fication, OCT4 and NANOG expression is sustained while SOX2
mRNA levels decrease, subsequently leading to primitive streak
induction (Wang et al., 2012). These results indicate that sup-
pression of TAZ/YAP/TEAD leads toME specification by sustain-
ingOCT4 andNANOG expression while simultaneously inducing
ME specific markers.
ME induction in hESCs is mediated by SMAD2/3-dependent
induction of FOXA2, EOMES, T, and GSC (D’Amour et al.,
2005; Kim et al., 2011). In the early stages of differentiation,
expression of these genes is also dependent on the pluripotency
transcription factors OCT4 and NANOG (Teo et al., 2011).
Accordingly, we observed sustained binding of OCT4 to TSO
elements along with SMAD2 after siRNA-mediated suppression
of TAZ/YAP (Figure 4D). Taken together, our results demonstrate
that TSO fulfills a repressive function in hESCs.
TAZ/YAP/TEAD Recruit Members of the NuRD Complex
to TSO Elements
Repressive functions for TAZ/YAP are not well described, and
these factors are more typically associated with transcriptional
activation (Varelas and Wrana, 2012). Recent reports indicate
that Scalloped, the TEAD homolog in Drosophila, acts as a
default repressor (Koontz et al., 2013), explaining why loss of
Scalloped does not show the dramatic effect caused by loss of
the TAZ/YAP homolog Yorkie. However, TAZ/YAP knockdown
closely phenocopies the knockdown of TEADs in hESCs, which
argues against a TEAD default repressor model in our system.
Interestingly, binding of TSO onME genes coincides with poised
enhancers that are silent under pluripotent conditions but can be
rapidly activated upon differentiation (Kim et al., 2011). These1618 Cell Reports 5, 1611–1624, December 26, 2013 ª2013 The Autelements are highly enriched for chromatin/histone-modifying
enzymes, which regulate accessibility and activity of these sites,
leading us to speculate that TSO might exert repressive func-
tions by interacting with chromatin/histone modifiers. Indeed,
when we analyzed our NANOG400 binding data, we found
peptides corresponding to components of the nucleosome re-
modelling and deacetylation (NuRD) complex (summarized in
Figure S6G). Of note, no NuRD components were found in our
in-house repository of AP-MS nonspecific protein interactors
(http://www.CRAPome.org; Mellacheruvu et al., 2013).
NuRD is a corepressor that associates with Oct4 in mESCs
(Liang et al., 2008) to maintain stem cell homeostasis by
balancing the expression of pluripotency and differentiation-
associated genes (Hu and Wade, 2012; Reynolds et al., 2012).
To investigate if NuRD contributes to TSO repressive functions,
we tested for cobinding of NuRD subunits CHD4 and MTA2 to
TSO elements in hESCs. Using ChIP-qPCR, we found that
both CHD4 and MTA2 bound to TSO sites in both ME and
pluripotency genes (FOXA2, T, GDF3, and NANOG) and that
association was typically reduced by knocking down TAZ/YAP
(Figure 5A). When we examined interactions of a constitutively
nuclear mutant of TAZ (TAZ-S89A) with NuRD components over-
expressed in 293T cells, we observed interaction with MTA1,
MTA2, MBD3, GATAD2A, GATAD2B, and CHD4, but not MTA3
or RBBP7 (Figures 5B and 5C). Similar results were obtained
when using a wild-type version of TAZ (data not shown). To
further confirm these interactions, we performed immunoprecip-
itation of endogenous YAP from hESC whole-cell lysates using
two distinct antibodies to YAP and observed coprecipitation of
endogenous GATAD2A (Figure 5D; data not shown) as well as
the expected partners, TEAD1 and LATS1. Thus, TAZ/YAP
interact with multiple components of the NuRD complex.
We next investigated if the NuRD complex contributed to
TSO-mediated ME suppression by performing a systematic
siRNA-mediated knockdown of NuRD components in hESCs.
Suppression of CHD4, the core catalytic subunit of the complex,
and MBD3, the subunit responsible for DNA binding, resulted in
extensive cell death of hESCs, whereas viability was maintained
when other components of the complex were knocked down to
varying degrees (Figure 5E). Although knockdown of RBBP4 and
7 (histone chaperones) had no effect on ME gene expression,
suppression of GATAD2B (subunit that binds unmodified histone
proteins) and to a lesser extent MTA1-3 (subunits responsible for
mediating DNA and protein-protein interactions) and CHD3
(ATPase subunit) led to induction of EOMES (Figure 5E) and
FOXA2 (data not shown). In summary, these results suggest
that the NuRD complex contributes to the repressor functions
of TSO.
TSOShunts SMAD2/3 Signaling fromPluripotency toME
Specification
Our data indicate that TSO prevents differentiation by suppress-
ing ME genes while simultaneously impeding aberrant expres-
sion of pluripotency genes, thereby stabilizing self-renewal and
pluripotency (Wang et al., 2012). To further dissect the molecular
mechanism governing ME specification by SMAD2/3 signaling,
we examined the TSO complex upon ME induction by morpho-
gens that model in vivo cell-fate decisions. For this, hESChors
Figure 5. Repression by TSO Is Mediated
by NuRD
(A) Components of the NuRD complex associate
with TSO peaks in hESCs. ChIP-qPCR with anti-
bodies to CHD4 (left) and MTA2 (right) was per-
formed on TSO loci after hESCs were treated with
siRNA for 72 hr as indicated. The amount of
precipitated DNA is represented as signal relative
to the amount of input DNA. Bars represent
mean ± SEM (n R 3). Mock precipitation using
species-matched normal IgG served as negative
control.
(B–D) Components of the NuRD complex interact
with TAZ and YAP. 33FLAG or single FLAG-tag-
ged components of the NuRD complex (MTA1-3 in
B and MBD3, GATAD2A/B, RBBP7, and CHD4
in C) were overexpressed in HEK293T cells along
with a predominantly nuclear mutant form of TAZ,
HA-TAZS89A. Endogenous YAP was precipitated
from hESC lysates and the purified complex was
probed for GATAD2A (D). TEAD1 and LATS1 are
known interaction partners of YAP and served as
positive controls. Representative experiments are
shown (n = 3).
(E) siRNA-mediated knockdown of NuRD com-
ponents induces EOMES expression. hESCs were
treated with siRNAs directed against NuRD
components for 72 hr. Expression levels were
normalized to GAPDH and HPRT and are pre-
sented relative to mock control. Bars represent
mean ± SEM (nR 3).colonies were cultured in 1 nM ACTIVIN in RPMI medium for
24 hr (D’Amour et al., 2005). This led to strong induction of
TSO-targeted ME genes, such as EOMES, T, and FOXA2
(Figure 6A). Interestingly, the pluripotency-associated genes
GDF3, POU5F1, and NANOG were also induced (Figure 6A),
consistent with their role in promoting the ME fate (Kim et al.,
2011). In order to identify the underlying molecular mechanism,
we performed ChIP-qPCR of selected TSO elements using the
TEAD4 antibody. For all analyzed targets, we observed loss of
TEAD4 binding to TSO sites upon ME specification (Figure 6B).
This is consistent with the notion that the TSO acts to suppress
these elements. On the other hand, induction of TSO genes is
dependent on SMAD2/3 signaling, as the genes remained silent
when cells were treated with RPMI medium without ACTIVIN
(Figure 6A). Importantly, differentiation did not affect expression
levels of the TEAD target gene CTGF, which is not controlled by
TSO (data not shown). This indicates that Hippo pathway activity
in cells committed to the ME fate is comparable to hESCs. More-
over, expression of the SMAD2/3 target gene SMAD7 was also
unaffected (data not shown), indicating comparable SMAD2/3
signaling activity under both conditions. These results indicate
that ME fate specification leads to selective disruption of the
TSO, with subsequent derepression of target genes, an eventCell Reports 5, 1611–1624, Dethat is not a general consequence of
alterations in Hippo or SMAD2/3 sig-
naling activity.
Our results might suggest that loss of
TSO is sufficient to allow for ME inductionwhen cells differentiate. However, SMAD2/3 signaling is essen-
tial for ME specification (Tam and Loebel, 2007). Furthermore,
SMADs are well known to cooperate with cell-type-specific
DNA binding partners to elicit cell-type-specific transcriptional
programs (Beyer et al., 2013). In particular, the forkhead domain
transcription factor FOXH1 is a key SMAD2/3 DNA binding part-
ner that is required for induction of ME in vivo (Labbe´ et al., 1998;
Hoodless et al., 2001; Yamamoto et al., 2001). This led us to
hypothesize that disruption of TSO during ME specification
might shunt the SMAD2/3 signal from cooperating with OCT4
during pluripotency maintenance to induction of ME through
FOXH1. Interestingly, the TSO targets EOMES, FOXA2, GSC,
LEFTY1, and GDF3 are SMAD2/3-FOXH1 ME targets, and
when we analyzed FOXH1 ChIP-seq data sets from hESCs and
ME precursors (Kim et al., 2011), we found that 20% of TSO-
bound regions resided within 100 bp of FOXH1 peaks. Visual
analysis of genomic sequences corresponding to overlapping
TSO/FOXH1 peaks revealed consensus FOXH1 sites close to
OCT4 binding sites on ME genes such asGSC and EOMES (Fig-
ure 6C). We confirmed FOXH1 binding to these regions by ChIP-
qPCR (Figure 7A) and showed that FOXH1 was present on TSO
peaks even in pluripotent conditions (Figure 7A). Importantly,
FOXH1 remained bound to these regions upon ME specificationcember 26, 2013 ª2013 The Authors 1619
Figure 6. TSO Is a Master Regulator of Mesendoderm Specification
(A) ME specification induces a subset of TSO genes.MEwas induced by treating hESCswith RPMImedium containing 1 nMActivin bA for 24 hr. Expression levels
of EOMES, T, FOXA2, GDF3, POU5F1, and NANOG were assessed by qPCR and normalized to GAPDH and HPRT. Bars represent mean ± SEM (nR 3).
(B) TEAD4 binding to TSO sites is lost after ME induction. ChIP-qPCR with an antibody against TEAD4 was performed after ME induction as indicated. The
amount of precipitated DNA is represented as signal relative to the amount of input DNA. Bars represent mean ± SEM (nR 3). Mock precipitation using species-
matched normal IgG served as negative control.
(C) FOXH1 associates with TSO onGSC and EOMES loci in hESCs. Individual peaks are represented by orange (TSO) or blue (FOXH1) bars. Conservation among
species is indicated as black bars. Inlets show sequences with putative OCT4 (red) and FOXH1 (blue) binding sites found within the peak regions.induced by depletion of TAZ/YAP. Thus, FOXH1 binding is inde-
pendent of the TSO complex. These results suggest that upon
ME specification, loss of the TSO repressive signal allows the
FOXH1 armof SMAD signaling tomediate activation ofME target
genes.
Our model predicts that ME induction caused by interfering
with TSO is FOXH1 dependent. To test this, we disrupted the
TSO in hESCs by knocking down TAZ/YAP either alone or
together with FOXH1 and assessed ME markers (Figures 7B
and S7A). As expected, knockdown of FOXH1 alone under plu-
ripotency conditions did not affect pluripotency gene expression
(POU5F1 and NANOG; Figure 7B), consistent with FOXH1 play-
ing no role in pluripotency maintenance. Knockdown of TAZ/
YAP, on the other hand, led to ectopic induction of the ME
markers EOMES and FOXA2 (Figures 4B and S6D). In striking
contrast, concomitant knockdown of FOXH1 and TAZ/YAP abol-
ished induction of ME genes (Figure 7B). These results demon-1620 Cell Reports 5, 1611–1624, December 26, 2013 ª2013 The Autstrate thatME induction upon disruption of the TSO is dependent
on the SMAD-FOXH1 pathway.
Our data provide for amodel of how hESCs interpret SMAD2/3
signaling in two different contexts: during pluripotency mainte-
nance and upon induction of the ME fate (Figure 7C). In partic-
ular, we show that SMADs engage with the Hippo pathway
effectors TAZ/YAP and TEADs, as well as the pluripotency factor
OCT4, to form the TSO, which collaborates with the NuRD core-
pressor complex to buffer expression of pluripotency genes
such as NANOG while repressing ME targets to maintain plurip-
otency and self-renewal. Furthermore, we demonstrate that key
TSO elements on ME genes also incorporate FOXH1 sites that
serve to shunt SMAD signaling to ME gene induction upon fate
specification. These studies thus reveal poised, switch-like reg-
ulatory elements that allow cells to differentially interpret the
same SMAD2/3 signaling pathway during both pluripotency
maintenance and cell-fate specification.hors
Figure 7. TSO and FOXH1 Form a Shunting
Switch for Mesendoderm Specification
(A) FOXH1 associates with TSO elements in
hESCs. hESCs were treated with siRNAs for 72 hr
as indicated and ChIP-qPCR with an antibody
against FOXH1 was performed. Note the nonlinear
scale of the y axis. The amount of precipitated
DNA is represented as signal relative to the
amount of input DNA. Bars represent mean ±
SEM (n R 3). Mock precipitation using species-
matched normal IgG served as negative control.
(B) FOXH1 controls TSO-mediated ME induction.
hESCs were treated with siRNAs for 72 hr as
indicated. Expression levels of POU5F1/OCT4,
NANOG, EOMES, and FOXA2 were normalized to
GAPDH and HPRT and are presented relative to
mock control. Bars represent mean ±SEM (nR 3).
(C) Schematic representation of TSO action in
pluripotent hESCs (left) and ME precursor cells
(right).DISCUSSION
Stem cells face a difficult challenge. They have to maintain the
proper balance of pluripotency factors and suppress differentia-
tion programs in order to maintain pluripotency. On the other
hand, upon appropriate external cues, these cells have to rapidly
adapt their transcriptional program to give rise to the required
cell lineage (Hu and Wade, 2012). How a common signaling
pathway is employed in both the maintenance of stemness
and specification of cell fate is thus a fundamental question in
stem cell biology. TGFb family signaling through the SMAD2/3
pathway is a key example, being required to both maintain plu-
ripotency and induce ME fate specification (Beyer et al., 2013).
We explored the problem of how distinct biological outputs are
controlled by the same signaling pathway using a proteomics
and ChIP-seq strategy. This uncovered a convergence of
SMAD2/3 signaling with the Hippo pathway and the pluripo-
tency factor OCT4 to form the TSO complex. In hESCs, TSO
occupies pluripotency-associated genes such as NANOG and
OCT4, as well as ME genes, and represses gene expression
via interaction with the NuRD corepressor complex, in agree-
ment with recent reports showing a balancing function of
NuRD in pluripotent cells (Hu and Wade, 2012; Reynolds et al.,
2012). Thus, in pluripotency conditions the TSO provides a buff-
ering capacity on pluripotency genes, while keeping the ME
program silent.Cell Reports 5, 1611–1624, DeStudies on transcriptional activities of
the downstream effectors of the Hippo
pathway have thus far focused on
transcriptional activation and mostly
neglected the possibility that TAZ and
YAP might act as repressors. It is, how-
ever, very common for transcription fac-
tors to modulate the expression of their
target genes both positively and nega-
tively, depending on the context. SMADs
and OCT4 are notable examples (Lianget al., 2008; Massague´ et al., 2005). A recent report showed
that also Yorkie, the Drosophila homolog of TAZ/YAP associates
with repressive complexes (Oh et al., 2013). Furthermore, it has
recently been shown that Sd/TEAD can act as a default re-
pressor in combination with Tgi/VGL4, with Tgi/VGL4 competed
away by Yki/TAZ/YAP, thus converting the site into an activator
(Koontz et al., 2013). This model explains why Sd mutant tissue
does not show the strong phenotype caused by loss of Yorkie.
However, in hESCs, the fact that knockdown of TEAD pheno-
copies TAZ/YAP knockdown argues against this mechanism.
Rather, our results support the notion that TSO directly recruits
NuRD. Regardless, these studies establish the concept that
TEADs and TAZ/YAP not only act as transcriptional activators
but also have repressive functions on target genes. These find-
ings thus shed light on an additional layer of regulation for tran-
scriptional output by Hippo signaling via TAZ and YAP.
Occupancy and repression of ME genes by TSOwould play an
obvious role in preventing ectopic differentiation of hESCs grown
under pluripotency conditions. However, our studies also re-
vealed that TSO targets a subset of pluripotency genes, in partic-
ularOCT4 andNANOG. In contrast, the pluripotency gene SOX2
is not occupied by TSO. Interestingly, recent studies demon-
strated that the selective expression of specific subsets of plu-
ripotency factors also plays a critical role in cell-fate choice. In
particular, OCT4 is required for primitive streak andME lineages,
while SOX2 directs neurectoderm specification (Niwa et al.,cember 26, 2013 ª2013 The Authors 1621
2000; Wang et al., 2012). Our discovery of TSO repressive com-
plexes converging onOCT4 andNANOG is consistent with these
findings. Indeed, loss of TSO resulted in upregulation of OCT4
and NANOG expression, indicating that in addition to releasing
ME genes, TSO loss also maintains expression of the subset of
pluripotency genes required for ME specification. This may be
critical to support expression of genes such as OCT4 once cells
initiate differentiation cascades and the pluripotency transcrip-
tional network collapses. These findings thus define a key role
for TSO in coordinating the broad gene expression program
associated with induction of the ME cell fate.
Our analysis of TSO complexes resident on target elements
also revealed rapid loss when ME was induced by culturing
hESCs in RPMI medium containing 1nM ACTIVIN. This raises
the question of what might be the molecular mechanism control-
ling TSO assembly. Our analyses of the TAZ/YAP target gene
CTGF and the SMAD target SMAD7 revealed no change in over-
all TAZ/YAP or SMAD2/3 activity upon ME induction. Therefore,
loss of the TSO is not due to changes in either Hippo or SMAD2/3
signaling per se, which suggests that other signaling pathways
altered uponME induction specifically interfere with TSO assem-
bly. Although we do not yet know how the TSO is regulated, it is
tempting to speculate that FGF signaling, which is critical for plu-
ripotency, might directly regulate the activity of the TSO.
FOXH1 is a master regulator of ME specification that is entirely
dependent on SMAD2/3 signaling to regulate target gene
expression (Labbe´ et al., 1998; Silvestri et al., 2008). Consistent
with this, Foxh1 is expressed broadly in the mouse epiblast prior
to ME specification (Hoodless et al., 2001; Yamamoto et al.,
2001) and is also expressed in hESCs, which are similar to
mouse epiblast-derived stem cells. Furthermore, we showed,
consistent with prior work, that FOXH1 occupies target elements
in hESCs even when cultured under pluripotency maintenance
conditions (Kim et al., 2011). In particular, key ME genes such
as FOXA2, EOMES, and GSC are also occupied by FOXH1,
where TSO is also present.We further showed that TSO is critical
to repress these genes under pluripotency conditions and that
subsequent induction of ME genes upon disruption of TSO is
dependent on FOXH1. Thus, constitutive FOXH1 binding allows
rapid shunting of SMAD2/3 signaling toward ME gene induction
when cells receive the appropriate differentiation cues. Taken
together, these studies identify a class of elements we define
as ‘‘switch elements’’ that repress target genes under pluripo-
tency conditions but then mediate rapid induction of cell-fate
specification genes (Figure 7B). These switch elements are
highly reminiscent of bivalent domains present at poised genes
in pluripotent cells and imply that transcription-factor-mediated
switch elements may be widespread, functioning to set appro-
priate transcriptional outputs in response to common cell sig-
naling pathways in different cellular contexts.
Our study shows how master transcriptional regulators, by
engaging with convergent signaling pathways, provide a combi-
natorial framework that allows a handful of morphogens to
regulate diverse biological outcomes throughout development.
These findings may have implications in understanding the dy-
namics of transcriptional responses in diseases such as cancer,
where alterations in tissue structure and somatic mutations
affect such contextual systems, ultimately leading to inappro-1622 Cell Reports 5, 1611–1624, December 26, 2013 ª2013 The Autpriate transcriptional outputs. A better understanding on how
stemness and cell-fate specification is regulated on the molecu-
lar level is also a prerequisite for the directed differentiation of
embryonic stem cells and induced pluripotent stem cells as
model systems for human diseases and for their future use in
regenerative medicine.
EXPERIMENTAL PROCEDURES
For further details, see the Supplemental Experimental Procedures.
Materials
Antibodies, primer sequences, and siRNA sequences are listed in Table S4.
Primers were obtained from Sigma-Aldrich and siRNAs from Dharmacon.
Cell Culture
hESCs (WA09, WiCell) were maintained in murine embryonic fibroblast condi-
tioned medium (Dulbecco’s modified Eagle’s medium [DMEM]/F12, 20%
knockout serum replacement [Invitrogen]; 0.1 mM nonessential amino acids
[Invitrogen]; 2 mM L-glutamine [Invitrogen]; 0.1 mM b-mercaptoethanol
[Invitrogen]; and 4 ng/ml basic FGF [Peprotech]) on hESC qualified Matrigel
(BD Bioscience) (Xu et al., 2001). Medium was changed daily and cells were
passaged by enzymatic dissociation (collagenase; Sigma) every 5–7 days at
a ratio of 1:6. HEK293T cells were cultured in DMEM (HyClone) containing
10% fetal bovine serum (HyClone).
Transfection of H9/WA09 with siRNA
Cells were dissociated to small cell lumps (5-15 cells) using Accutase
(Invitrogen) and seeded on Matrigel in MEF conditioned medium. After 24 hr,
cells were transfected with 60 nM siRNA and 1.5 ml RNAimax (Invitrogen)
mixed in Opti-MEM (Invitrogen) for 6 hr. After 6 hr, fresh medium was added
so that the siRNA concentration was 15 nM. The medium was changed
24 hr after the initial transfection.
DNA Pull-Down
30 ml of streptavidin-Agarose beads (Thermo Scientific) were washed with
binding buffer (20 mM HEPES [pH 7.5], 2.5 mM KCl, 1 mM DTT, 20% glycerol,
0.02% NP40), incubated with 300 pmol biotinylated double-stranded oligo
nucleotides or 1 mg PCR product in 1ml binding buffer for 30 min at room tem-
perature and washed again. Cells were lysed in 1 ml TNTE buffer (50 mM Tris/
HCl [pH7.6], 150 mM NaCl, 0.5% Triton X-100, 1 mM EDTA, protease and
phosphatase inhibitors) per 10 cm dish. Beads were incubated with 350 ml
cell lysate and 10 mg dIdC (Sigma) in a total volume of 1.4 ml Binding buffer
for 5 hr at 4C. Beads were either repetitively washed with binding buffer,
boiled with 23 Laemmli buffer, and subjected to SDS-PAGE, or prepared for
mass spectrometry analysis. For the latter, beads were washed twice with
binding buffer and three times with 50 mM ammonium bicarbonate and
analyzed by mass spectrometry as previously described (Varelas et al., 2010).
ACCESSION NUMBERS
Microarray and ChIP-seq data are available in the Gene Expression Omnibus
database (http://www.ncbi.nlm.nih.gov/geo/) under the accession number
GSE52440.
SUPPLEMENTAL INFORMATION
Supplemental information includes Supplemental Experimental Procedures,
seven figures, and four tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2013.11.021.
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